Cargando…
Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer
This dose escalation study was designed to determine the maximum tolerated dose (MTD) and recommended doses (RDs) of 5-fluorouracil (5FU), folinic acid and oxaliplatin (FOLFOX) with concomitant radiotherapy in inoperable/metastatic oesophageal squamous cell carcinoma or adenocarcinoma. Patients rece...
Autores principales: | Conroy, T, Viret, F, François, E, Seitz, J F, Boige, V, Ducreux, M, Ychou, M, Metges, J P, Giovannini, M, Yataghene, Y, Peiffert, D |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579679/ https://www.ncbi.nlm.nih.gov/pubmed/18841161 http://dx.doi.org/10.1038/sj.bjc.6604708 |
Ejemplares similares
-
Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer
por: Conroy, T, et al.
Publicado: (2010) -
Fluorouracil/folinic acid/oxaliplatin: Various toxicities: 2 case reports
Publicado: (2021) -
Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity
por: Fischel, J L, et al.
Publicado: (2002) -
Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines
por: Fischel, J-L, et al.
Publicado: (2001) -
Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
por: Bensmaïne, M A, et al.
Publicado: (2001)